Lightstone Ventures

Lightstone Ventures is a global venture capital firm dedicated to investing in early-stage biotech and medtech companies. Founded in 2012, the firm focuses on translating novel scientific breakthroughs into clinically and commercially meaningful therapies. With offices in Boston, Menlo Park, Dublin, and Singapore, Lightstone Ventures has a track record of leading deals resulting in numerous acquisitions and initial public offerings over the past two decades.

The firm's investment strategy centers on partnering with visionary entrepreneurs to develop innovative therapeutics and technologies that aim to transform patient outcomes. Lightstone Ventures has been actively involved in supporting its portfolio companies through significant financing rounds, including a $120 million Series B round for FIRE1 in January 2025 and a $150 million Series C round for Atsena Therapeutics in April 2025. Additionally, the firm played a pivotal role in the successful public listing of Shoulder Innovations on the New York Stock Exchange in July 2025.

Lightstone Ventures' commitment to advancing healthcare innovation is further demonstrated by its strategic advisory and leadership enhancements. In January 2025, the firm appointed Dr. H. Martin Seidel as an Advisor, bringing extensive experience in R&D and business development. Furthermore, in August 2025, Caroline Gaynor, a Partner at Lightstone Ventures, was elected Chair of the Irish Venture Capital and Private Equity Association, underscoring the firm's leadership in the venture capital community.